Hypertension, chronic kidney disease, and the development of cardiovascular risk: a joint primacy  by Middleton, John P. & Pun, Patrick H.
commentar y
 Patients with diminished kidney 
 function are exposed to a high risk of 
complications from vascular and / or 
cardiac disease, but how this risk evolves 
is not entirely clear. In patients with pre-
existing cardiac disease, the estimated 
risk of death from any cause increases as 
glomerular f i ltration rate (GFR) 
declines, and patients with GFRs less 
than 20  ml / min are six times more likely 
to die than those with GFRs above 
60  ml / min. 1 In a remarkable study of 
more than a million Kaiser enrollees in 
California, kidney function impairment 
independently and incrementally pre-
dicted subsequent cardiac events, hos-
pitalization, and overall mortality. 2 In 
patients with end-stage kidney disease, 
the risk is even greater. A patient who 
initiates maintenance hemodialysis in 
the United States is likely to live only 8.4 
more years, and the predicted lifespan 
is truncated compared with that of the 
general population because of the nearly 
20-fold greater cardiovascular risk. 3 Th e 
types of cardiovascular events that are 
commonly observed among chronic 
kidney disease (CKD) patients range 
from ischemic events that mandate 
revascularization to the cataclysm of 
sudden cardiac arrest. 4 Th ese and other 
observations cement an association 
between CKD and cardiovascular dis-
ease, but the source of this association 
remains elusive. ( Figure 1 )
 In these and related studies, the observed 
association between the degree of CKD and 
cardiovascular risk persists despite adjust-
ments for comorbid diseases and risk con-
tributors identified in the general 
population. Th erefore, a great deal of eff ort 
is expended in identifying unique CKD-
specifi c variables that promote cardiovas-
cular illness. These nontraditional risks 
include indolent systemic infl ammation, 
disordered composition of circulating lip-
ids, abnormal mineral metabolism, 
endothelial cell dysfunction, disordered 
autonomic function, elevated uric acid con-
centrations, abnormal concentrations of 
serum electrolytes, and fl uctuations in vol-
ume status. 5 – 7 Factors that result from 
dialysis methods further enhance cardio-
vascular risk, probably because of intermit-
tent and at times drastic exposure to 
ultrafiltration and to electrolytes in 
 dialysate. 8 Th e established environment of 
uremia, the metabolic responses to that 
state, or even practice habits could be the 
dominant causes of abnormal cardiac and 
vascular function in CKD. 
 Concurrently with these conditions, 
patients with CKD certainly suff er from a 
number of comorbid illnesses that can 
simultaneously promote kidney and cardio-
vascular diseases. One of the most consist-
ent risks for cardiovascular  disease in the 
general population is hyper tension, and in 
the absence of discernible kidney disease, 
elevation of blood pressure increases the 
risk of cardiac and vascular disease. Fur-
thermore, many large clinical trials conclu-
sively demonstrate that pharmacologic 
lowering of systemic blood pressure 
decreases cardiovascular morbidity in 
patients with hypertension. Added cardiac 
or renal protection may result from medi-
cations that target the renin – angiotensin –
 aldosterone system, particularly in patients 
with CKD attri buted to diabetes. 9 When 
the identity of distinct contributors is 
sought in the relationship between cardio-
vascular risk and CKD, one near constant 
is the infl uence of hypertension. Hyperten-
sion oft en presents as a diff erent phenotype 
in CKD, with a greater likelihood of salt 
sensitivity, a higher frequency of hyperten-
sive emergencies, and a diff erent 24-h pro-
fi le of blood pressure (such as the lack of a 
nocturnal dip in blood pressure). 10 Perhaps 
as a result of this, abnormal ventricular 
structure is common in patients with CKD. 
Left  ventricular hypertrophy is present in 
25 – 40 % of patients who initiate dialy-
sis. 11,12 Th erefore, it would stand to reason 
that hypertension is an important partici-
pant in the pathogenesis of CKD-related 
cardiac and vascular disease. 
 Kendrick and colleagues 13 (this issue) 
address the important question of interac-
tion between systemic blood pressure and 
atheromatous disease in patients with 
CKD. Th ey performed an analysis of the 
INVADE (Intervention Project on Cere-
brovascular Diseases and Dementia in the 
Community of Ebersberg, Bavaria), an 
observational study of a cohort of elderly 
subjects in Germany, some of whom had 
early stages of CKD. Data were collected 
from subject self-assessment forms, an ini-
tial physical examination, laboratory stud-
ies, and ultrasound measurements of 
carotid intima – media thickness (IMT). 
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Th e latter measurement is substantiated as 
a measure of early carotid atherosclerosis 
and a surrogate marker of cardiovascular 
risk. Changes in IMT were also determined 
aft er a 4-year follow-up. Th e authors ’ obser-
vations suggest that IMT is directly corre-
lated with baseline systolic blood pressure 
and also with baseline estimated GFR. Fur-
thermore, progression of IMT over time 
was related to baseline blood pressure, and 
this eff ect was more pronounced among 
patients with diminished GFR. 
 Th e authors acknowledge limitations of 
this interesting study. First, the most strik-
ing correlations were made on the basis of 
baseline measurements of blood pressure 
and kidney function. Th erefore, it is diffi  cult 
to apply this information to follow-up treat-
ments or to recommended blood pressure 
goals. Second, even though a trend was 
observed for major vascular events, the 
strongest correlations were found for the 
surrogate measure of IMT and baseline 
blood pressure. Th ird, as these observations 
were from a specifi c cohort of subjects in 
Germany, it is unclear how the study will 
extend to patient groups of diff erent demo-
graphic mixes or with more advanced kid-
ney disease. Fourth, the analysis did not 
examine whether microalbuminuria inter-
acted signifi cantly with initial blood pres-
sure or with the extent of CKD. 14 Finally, 
the observed changes in IMT through the 
course of the study were relatively modest. 
 Kendrick and colleagues 13 clearly dem-
onstrate a signifi cant interaction between 
blood pressure and baseline kidney function. 
More importantly, the authors provide a 
compelling argument that blood pressure 
targets even lower than those currently 
applied (that is, systolic pressure less than 
130  mm  Hg) should be considered in 
patients with CKD in order to reduce car-
diac and vascular illness. 15 Although more 
studies will be needed to merit this 
approach, application of a new blood pres-
sure goal would result in a radical change 
in clinical interventions. In the United 
States, for example, where approximately 
10 % of the adult population has CKD, 
only 13 – 31 % of at-risk patients have blood 
pressure below 130 / 80  mm  Hg. 16,17 If a 
more aggressive blood pressure treatment 
goal is adopted in patients with CKD in 
order to reduce the cardiovascular risk, it 
will likely create dramatic increases in the 
currently low rate of prescription of angi-
otensin-converting enzyme inhibitors 
(25.1 % ), of diuretics (18.5 % ), or of two or 
more antihypertensive medications 
(25.1 % ). 17 Despite poor rates of blood 
pressure control among CKD patients, we 
know that it is feasible to achieve aggres-
sive blood pressure targets, at least in the 
context of a randomized controlled pro-
spective clinical trial. In the African 
American Study of Kidney Disease and 
Hypertension (AASK), subjects with CKD 
were able to attain a mean blood pressure 
of 128 / 78 when the specifi ed target was a 
mean arterial pressure less than 
92  mm  Hg. 18 AASK and other trials that 
have aimed to achieve lower blood pres-
sures in patients with CKD have not been 
able to demonstrate signifi cant cardiovas-
cular benefi ts of this aggressive approach. 
However, because of issues of study power 
and duration of follow-up, these studies 
still leave open the possibility that lower 
blood pressure goals in CKD patients will 
improve clinical outcomes. 
 Even more than creating a situation of 
equipoise, the question of how to manage 
cardiovascular risk in CKD places clini-
cians and patients in a high-stakes gamble. 
On one hand we are aware of the extraor-
dinarily high rate of cardiovascular disease 
in CKD, but on the other hand we have an 
array of prospective clinical trials that have 
failed to demonstrate a benefi t of interven-
tion. Th us we are forced to make manage-
ment decisions based on the best evidence 
at hand, even if that evidence is imperfect. 
Th e observations of Kendrick  et al. 13 sug-
gest that early and aggressive blood pres-
sure lowering in CKD should be 
considered as a vital intervention. 
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 Figure 1  |  Joint contribution of CKD and hypertension to cardiac risk . CKD, chronic kidney 
disease; GFR, glomerular filtration rate. 
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 The promise of biomarkers for 
personalized renal cancer care 
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 Biomarkers hold promise for personalizing renal cancer care by 
potentially identifying patients most likely to benefit from novel 
therapies. Porta and colleagues report that among subjects with 
advanced renal-cell carcinoma receiving sunitinib treatment, those with 
above-normal levels of the circulating biomarkers vascular endothelial 
growth factor and neutrophil gelatinase-associated lipocalin displayed 
significantly lower progression-free survival times. This Commentary 
reviews the current status of these biomarkers with respect to 
methodological issues, specificity, and biological plausibility. 
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 The era of personalized medicine is well 
upon us. Ushered in by the remarkable 
genomic and proteomic advances in our 
understanding of health and disease, 
personalized medicine promises a more 
precise determination of disease predis-
position, diagnosis, and prognosis, 
earlier preventive and therapeutic inter-
ventions, a more effi  cient drug develop-
ment process, and a safer and more 
fi scally responsive approach to medicine. 
Biomarkers are the essential tools for the 
implementation of personalized medi-
cine. Broadly defi ned as characteristics 
that are objectively evaluated as indica-
tors of normal biological processes, path-
ogenic processes, or pharmacologic 
responses, biomarkers have already revo-
lutionized several facets of medicine. 
Particularly in the fi eld of oncology, spe-
cifi c biomarkers such as HER2 (erbB2) 
and EGFR now allow us to individualize 
therapies for patients with breast and 
colorectal cancers. However, we have 
only begun to scratch the tip of the 
 proverbial iceberg — as medical break-
throughs continue to identify novel 
agents for malignancies that are poten-
tially eff ective but also inevitably toxic 
and expensive, biomarkers will be 
indispensible for patient selection, risk 
stratifi cation, and prognostication. 
 Consider the case in hand: renal-cell car-
cinoma (RCC), the most common kidney 
cancer in adults and clearly the most lethal 
of all advanced genitourinary tumors. For-
tunately, an improved understanding of the 
underlying molecular bio logy has begun to 
identify novel targeted therapies. In kidney 
tubule cells, the pro duct of the  VHL tumor 
suppressor gene normally inhibits the pro-
duction of hypoxia-inducible factors such 
as vascular endothelial growth factor 
(VEGF) and platelet-derived growth factor 
(PDGF). Inactivation of the  VHL gene, as 
occurs in the majority of clear-cell carcino-
mas (the predominant type of renal-cell 
carcinoma), results in overexpression of 
these factors, and stimulation of the cog-
nate VEGF and PDGF receptors, respec-
tively. Persistent activation of the receptors ’ 
intrinsic tyrosine kinase results in signaling 
through cellular pathways that stimulate 
growth, proliferation, and angiogenesis and 
inhibit apoptosis, thereby resulting in met-
astatic RCC. 1 Sunitinib, an orally active 
agent that inhibits the receptor tyrosine 
kinases VEGFR types 1 and 2 and PDGFR-
  and PDGFR-  , has shown promise in 
prolonging progression-free survival in 
some patients with advanced RCC. 2 How-
ever, individual responses have varied 
unpredictably, side eff ects are myriad, and 
overall mortality has remained largely una-
bated. Herein lies the dilemma — how do 
we personalize this novel therapy to best 
identify the subset of patients who are most 
likely to benefi t from it? 
 Porta and colleagues 3 (this issue) have 
appropriately called on biomarkers to 
tackle this question. In 85 subjects with 
advanced RCC who were treated with 
sunitinib, the authors have compared the 
ability of an existing clinicopathologic 
scoring system (Motzer criteria) versus 
serum biomarkers at enrollment as pre-
dictors of progression-free survival. In 
their cohort, the baseline concentrations 
of both chosen biomarkers, VEGF and 
neutrophil gelatinase-associated lipoca-
lin (NGAL), were found to correlate with 
progression-free survival, whereas the 
Motzer score did not. When subjects 
were dichotomized to normal versus 
high circulating biomarker levels, those 
with values above a threshold (determined 
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